0001144204-18-040076.txt : 20180726
0001144204-18-040076.hdr.sgml : 20180726
20180726135652
ACCESSION NUMBER: 0001144204-18-040076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180724
FILED AS OF DATE: 20180726
DATE AS OF CHANGE: 20180726
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gaston-Dreyfus Remi
CENTRAL INDEX KEY: 0001716639
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54717
FILM NUMBER: 18971227
MAIL ADDRESS:
STREET 1: 46 RUE PIERRE CHARRON
CITY: PARIS
STATE: I0
ZIP: 75008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionik Laboratories Corp.
CENTRAL INDEX KEY: 0001508381
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 271340346
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 483 BAY STREET
STREET 2: N105
CITY: TORONTO
STATE: A6
ZIP: M5G2C9
BUSINESS PHONE: 1.416.640.7887
MAIL ADDRESS:
STREET 1: 483 BAY STREET
STREET 2: N105
CITY: TORONTO
STATE: A6
ZIP: M5G2C9
FORMER COMPANY:
FORMER CONFORMED NAME: Drywave Technologies, Inc.
DATE OF NAME CHANGE: 20130814
FORMER COMPANY:
FORMER CONFORMED NAME: Strategic Dental Management Corp.
DATE OF NAME CHANGE: 20101220
4
1
tv499376_4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-07-24
0
0001508381
Bionik Laboratories Corp.
BNKL
0001716639
Gaston-Dreyfus Remi
C/O BIONIK LABORATORIES CORP.
483 BAY STREET, N105
TORONTO
A6
M5G2C9
ONTARIO, CANADA
1
0
1
0
Common Stock
2018-07-24
4
C
0
43468547
0.0513
A
134672664
I
Shares held through RGD Investissements and Lombard International Assurance SA
Effective as of July 20, 2018, an aggregate amount of $2,006,943 in convertible promissory notes issued to RGD Investissements (the "Notes") converted in accordance with their terms into 43,468,547 shares of the Issuer's common stock. For purposes of the filing of this Form 4, the transaction date is deemed to be July 24, 2018, as that was the date that the Issuer preliminarily determined the number of shares of common stock that the Notes were convertible into in accordance with the terms of the Notes.
The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction.
/s/ Remi Gaston-Dreyfus
2018-07-25